14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ESPR ranks #14339 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$3.78 (0.27%)

Volume: 1M

Closed: Jan 21, 2022

Hollow Logo Score: -3.337

Esperion Therapeutics Stock Forecast

$3.78 (0.27%)

Volume: 1M

Closed: Jan 21, 2022

Score Hollow Logo -3.337

Esperion Therapeutics Company Profile

3891 Ranchero Drive

Ann Arbor MI 48108



Esperion Therapeutics


Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Its lead product candidate is ETC-1002 or Bempedoic acid, an inhibitor of ATP Citrate Lyase, an enzyme on the cholesterol biosynthesis pathway that is in Phase III long-term safety and tolerability study to treat patients with hypercholesterolemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol, and up-regulates LDL-receptors, resulting in increased LDL-C clearance and reduced plasma levels of LDL-C. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE